Evidence map›Paper›PMID 42353819›Full record

ArticleGenes2026

Biallelic ATG9B Variants Define a Novel Autophagy-Related Neurodevelopmental Disorder with Cerebellar Ataxia.

Seval Kılıç, Kerem Esmen, Jean-Loup Méreaux, Ayşe Miray Oto, Tansu Bilge Kose, Melike Sever-Bahcekapili, Emine Eren-Koçak, Şeyda Demir, A Semra Hız, Erum Afzal and 10 more

Abstract read
In one paragraph

Article in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Seval KılıçRare and Undiagnosed Diseases Platform-RUDIP, Izmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.
Kerem EsmenRare and Undiagnosed Diseases Platform-RUDIP, Izmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.ORCID 0000-0002-5815-6978
Jean-Loup MéreauxSorbonne Université, Institut Du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, University Hospital Pitié-Salpêtrière, 75013 Paris, France.ORCID 0000-0002-4279-7252
Ayşe Miray OtoRare and Undiagnosed Diseases Platform-RUDIP, Izmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.ORCID 0009-0006-2944-4336
Tansu Bilge KoseInstitute of Neurological Sciences and Psychiatry, Hacettepe University, 06230 Ankara, Türkiye.
Melike Sever-BahcekapiliInstitute of Neurological Sciences and Psychiatry, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0002-0592-9666
Emine Eren-KoçakInstitute of Neurological Sciences and Psychiatry, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0002-4507-3110
Şeyda DemirDepartment of Histology and Embryology, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Türkiye.ORCID 0000-0002-7726-996X
A Semra HızRare and Undiagnosed Diseases Platform-RUDIP, Izmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.
Erum AfzalDepartment of Developmental and Behavioral Pediatrics, Children's Hospital and Institute of Child Health, Multan 60000, Punjab, Pakistan.
Zahra FiroozfarDepartment of Neuromuscular Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.ORCID 0009-0009-3927-6796
Gökhan KarakülahIzmir International Biomedicine and Genome Institute, Dokuz Eylul University, 35330 Izmir, Türkiye.ORCID 0000-0001-6706-1375
H Alper BagriyanikDepartment of Histology and Embryology, Faculty of Medicine, Dokuz Eylul University, 35330 Izmir, Türkiye.
Léna Guillot-NoelSorbonne Université, Institut Du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, University Hospital Pitié-Salpêtrière, 75013 Paris, France.ORCID 0000-0002-0287-3361
Giulia CoarelliSorbonne Université, Institut Du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, University Hospital Pitié-Salpêtrière, 75013 Paris, France.
Henry HouldenDepartment of Neuromuscular Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Stephanie EfthymiouDepartment of Neuromuscular Disorders, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.ORCID 0000-0003-4900-9877
Alexandra DurrSorbonne Université, Institut Du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, APHP, University Hospital Pitié-Salpêtrière, 75013 Paris, France.
Mehmet ÖztürkIzmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.ORCID 0000-0002-6092-9706
M Kasim DirilRare and Undiagnosed Diseases Platform-RUDIP, Izmir Biomedicine and Genome Center, 35330 Izmir, Türkiye.ORCID 0000-0002-3644-4178

Funding

Dokuz Eylül University DEU-BAP Project no: 2014.KB.SAG.054European Union Horizon 2020 ERA Chairs program RareBoost project, Grant no: 952346Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 122Z025, 120S396, 121S347Wellcome Trust 221951/Z/20/Z
6 · The paper itself

Abstract

BACKGROUND/

objectivesAutophagy is a highly conserved eukaryotic cellular process whose dysfunction results in human pathologies including cancer and neurodegenerative disease. First identified in yeast,

methodsHere we report, for the first time, variants in human

resultsThe first variant is an 11-nucleotide deletion resulting in a frameshift. A premature stop codon is added and the C-terminal cytosolic domain of ATG9B protein is truncated. The second one is a point mutation that changes a critical amino acid in the transmembrane domain. The third variant is a 2-nucleotide deletion causing a different truncation product. Patients presented with diverse neurodevelopmental anomalies including intellectual disability, behavioral abnormalities, congenital cerebellar ataxia, mild cerebellar atrophy, and microcephaly. Since human ATG9B is expressed specifically in the placenta, we hypothesized that the disease pathology originates during placental development. To characterize the effects of the first frameshift mutation and gain insight into the specific functions of ATG9B in a physiological setting, we used mammalian cells and a knock-in mouse model. Truncated ATG9B was not stable when expressed in cells. It was localized to perinuclear vesicles like the WT protein, but not to peripheral vesicles. Homozygous knock-in mice were viable, fertile, and displayed no gross phenotypical abnormalities. Histomorphometry analysis of the placenta layers did not reveal a significant difference between mutant and control embryos. The assessments of neurobehavioral tests were similar in wild-type and homozygous knock-in mice. However, knock-in mice had a reduced fear memory trend, which is an amygdala-involved response.

conclusionsIn this study, we describe a new rare disease linked to

Indexed as

AutophagyAutophagy-Related ProteinsCerebellar AtaxiaNeurodevelopmental DisordersAllelesAnimalsChildChild, PreschoolConsanguinityFemaleHumansMaleMicePedigreeAutophagy-Related ProteinsATG9Bautophagygenetically engineered mouse modelsrare disease

Identifiers

PMID42353819
PMCPMC13299270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.